![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, August 28, 2020 10:17:36 AM
August 28, 2020
Mary Caffrey , Gianna Melillo
A new analysis from the REDUCE-IT trial finds that cardiovascular benefits of Vascepa are consistent no matter what type of statin a patient takes for cholesterol.
The benefits of taking icosapent ethyl, the purified omega-3 fatty acid sold as Vascepa, were consistent across statins of different strengths and types, according to the latest data from the REDUCE-IT study presented during the 2020 Congress of the European Society of Cardiology (ESC), being presented in a virtual format.
Icosapent ethyl, first approved to treat high triglycerides, has since received a cardiovascular (CV) indication after REDUCE-IT showed that a 4g per day dose reduced the risk of first-time CV events by 25% and first and future events by 30%. Subsequent studies have sought to better understand the mechanisms of how icosapent ethyl produces these results.
In this latest round of data from the study, lead study author Deepak Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, sought to examine the relationship between low density lipoprotein (LDL) cholesterol pathways and the CV benefits of icosapent ethyl, by examining whether the there were major differences in benefit by statin type or by statin group (lipophilic vs lipophobic); according to the abstract presented at ESC, 96.1% of the patients in the study fell into one of these statin groups.
In an interview, Bhatt told The American Journal of Managed Care® that the analysis further supports the main findings of REDUCE-IT. “We looked at patients who are on really intense statins, things like atorvastatin and rosuvastatin, or more modest types of statins, such as simvastatin or pravastatin,” he said. “We also bunched it by hydrophobic and hydrophilic statins.”
“The bottom line was, any way you sliced it there was a benefit, a consistent benefit favoring icosapent ethyl versus placebo, irrespective of the actual statin type or category of statin.”
Results. CV outcomes were similar across different statin types (interaction, P = .61) and across lipophilic/lipophobic categories (interaction, P = .51). Hazard ratio (HR) results by individual statin type were as follows, all favoring icosapent ethyl (all 95% CI):
Atorvastatin: HR, 0.80 (0.68-0.94), P = .0054
Simvastatin: HR, 0.76 (0.64-0.90), P = .0017
Rosuvastatin: HR, 0.68 (0.54-0.85), P = .0009
Pravastatin: HR, 0.88 (0.62-1.25), P = .47
Among the 2 main statin groups, the HR on lipophilic statins was 0.78 (0.69-0.87), P < .0001; for lipophobic statins, HR, 0.73 (0.66-0.88), P = .0012.
In the abstract, Bhatt and co-authors wrote that the LDL cholesterol changes and CV risk reduction in the study “appear independent of the type of concomitant statin therapy.”
They concluded, “These data provide clinicians with additional insight regarding concomitant statin therapy considerations when prescribing icosapent ethyl and suggest there are important mechanisms of action for the substantial CV risk reduction observed with icosapent ethyl that are distinct from the LDL receptor pathway.”
Reference
Bhatt DL, Miller M, Steg P, for the REDUCE-IT Investigators. REDUCE-IT outcomes by baseline statin type. Presented at ESC Congress 2020:. Abstract 218514.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
FEATURED North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM